ICU Medication MasterclassSeptic shock • ARDS • Severe CAP • Adrenal crisis • HLH/MAS

Corticosteroids & Immunomodulation in Critical Illness

A syndrome-first guide to glucocorticoids and selected immunomodulators: distinguish replacement from anti-inflammatory therapy, use steroid-equivalent thinking correctly, and avoid carrying one trial regimen into every ICU diagnosis.

← Medication Library

Differentiate stress-dose replacement, shock adjunct therapy and disease-modifying anti-inflammatory therapy.

Choose hydrocortisone, methylprednisolone, dexamethasone or fludrocortisone by physiology and indication rather than potency alone.

Recognize when corticosteroids are recommended, conditional, uncertain or harmful in common ICU syndromes.

Use anakinra only in a defined hyperinflammatory phenotype with specialist input rather than for isolated ferritin elevation.

Monitor glucose, infection, delirium, neuromuscular weakness, sodium/potassium and cumulative exposure.

Steroids in the ICU

Detailed steroid equivalence, tapering and syndrome-specific visual teaching.

Open →

HLH / MAS

Full diagnostic and treatment framework for hyperinflammation.

Open →

Core agents

Choose by physiology, not by habit

The table below is a selection framework. Open the individual monograph for exact dosing, preparation, renal/CRRT/IHD adjustment, interactions and evidence traceability.

Hydrocortisone

Short-Acting Glucocorticoid with Clinically Relevant Mineralocorticoid Activity

Core agent

ICU role: Short-acting glucocorticoid with meaningful mineralocorticoid activity.

Choose: Adrenal crisis and the usual corticosteroid used when steroids are chosen for septic shock; also a severe-CAP trial/guideline option.

Hesitate: Do not treat sepsis without shock solely because infection is present; monitor hyperglycemia, sodium/fluid retention and myopathy.

Monitor: MAP/vasopressor trajectory, glucose, Na/K, infection and neuromuscular status.

Methylprednisolone

Intermediate-Acting Synthetic Glucocorticoid with Minimal Mineralocorticoid Activity

Core agent

ICU role: Intermediate-acting glucocorticoid with minimal mineralocorticoid activity.

Choose: Useful in selected severe airway/inflammatory lung disease and disease-specific steroid protocols.

Hesitate: Avoid reflex dose escalation; prolonged exposure increases hyperglycemia, infection, delirium and weakness.

Monitor: Glucose, infection, mental status and muscle strength.

Dexamethasone

Long-Acting Synthetic Fluorinated Glucocorticoid (High Anti-Inflammatory Potency) with Negligible Mineralocorticoid Activity

Core agent

ICU role: Long-acting, potent glucocorticoid with negligible mineralocorticoid effect.

Choose: Useful for bacterial meningitis timing, selected cerebral vasogenic edema and disease-specific ARDS protocols.

Hesitate: Do not use to treat acute traumatic brain injury; long biologic effect prolongs metabolic/neuropsychiatric toxicity.

Monitor: Glucose, neurologic status, infection and cumulative exposure.

Fludrocortisone

Potent Mineralocorticoid with Glucocorticoid Activity

Core agent

ICU role: Potent oral mineralocorticoid.

Choose: Primary adrenal-insufficiency replacement after the acute stress-dose phase; may be paired with hydrocortisone when deliberately following an APROCCHSS-style septic-shock regimen.

Hesitate: Not a substitute for stress-dose hydrocortisone in adrenal crisis; can worsen edema, hypertension and hypokalemia.

Monitor: BP, volume status, sodium, potassium and renin in chronic replacement.

Anakinra

Interleukin-1 Receptor Antagonist

Core agent

ICU role: IL-1 receptor antagonist used off-label for selected hyperinflammatory syndromes.

Choose: Consider with hematology/rheumatology in a compatible MAS/secondary-HLH phenotype when the trigger and severity support IL-1 blockade.

Hesitate: No universal adult ICU dose or ferritin threshold; renal accumulation and infection risk matter.

Monitor: CBC, renal function, infection trajectory, ferritin/fibrinogen and organ-failure response.

Agent	ICU role	Why I choose it	Why I hesitate	What I monitor
Hydrocortisone Short-Acting Glucocorticoid with Clinically Relevant Mineralocorticoid Activity	Short-acting glucocorticoid with meaningful mineralocorticoid activity.	✓ Adrenal crisis and the usual corticosteroid used when steroids are chosen for septic shock; also a severe-CAP trial/guideline option.	✕ Do not treat sepsis without shock solely because infection is present; monitor hyperglycemia, sodium/fluid retention and myopathy.	MAP/vasopressor trajectory, glucose, Na/K, infection and neuromuscular status.
Methylprednisolone Intermediate-Acting Synthetic Glucocorticoid with Minimal Mineralocorticoid Activity	Intermediate-acting glucocorticoid with minimal mineralocorticoid activity.	✓ Useful in selected severe airway/inflammatory lung disease and disease-specific steroid protocols.	✕ Avoid reflex dose escalation; prolonged exposure increases hyperglycemia, infection, delirium and weakness.	Glucose, infection, mental status and muscle strength.
Dexamethasone Long-Acting Synthetic Fluorinated Glucocorticoid (High Anti-Inflammatory Potency) with Negligible Mineralocorticoid Activity	Long-acting, potent glucocorticoid with negligible mineralocorticoid effect.	✓ Useful for bacterial meningitis timing, selected cerebral vasogenic edema and disease-specific ARDS protocols.	✕ Do not use to treat acute traumatic brain injury; long biologic effect prolongs metabolic/neuropsychiatric toxicity.	Glucose, neurologic status, infection and cumulative exposure.
Fludrocortisone Potent Mineralocorticoid with Glucocorticoid Activity	Potent oral mineralocorticoid.	✓ Primary adrenal-insufficiency replacement after the acute stress-dose phase; may be paired with hydrocortisone when deliberately following an APROCCHSS-style septic-shock regimen.	✕ Not a substitute for stress-dose hydrocortisone in adrenal crisis; can worsen edema, hypertension and hypokalemia.	BP, volume status, sodium, potassium and renin in chronic replacement.
Anakinra Interleukin-1 Receptor Antagonist	IL-1 receptor antagonist used off-label for selected hyperinflammatory syndromes.	✓ Consider with hematology/rheumatology in a compatible MAS/secondary-HLH phenotype when the trigger and severity support IL-1 blockade.	✕ No universal adult ICU dose or ferritin threshold; renal accumulation and infection risk matter.	CBC, renal function, infection trajectory, ferritin/fibrinogen and organ-failure response.

Clinical decision matrix

What changes the drug choice?

Septic shock remains vasopressor dependent after initial resuscitation

Preferred reasoning: Hydrocortisone using a current septic-shock regimen when the team chooses corticosteroids.

Avoid: High-dose short-duration steroid pulses or waiting for an ACTH test before treating shock.

Why: SCCM supports corticosteroids in adult septic shock and recommends against high-dose/short-duration regimens.

Known Addison disease with vomiting, shock and hyponatremia

Preferred reasoning: Immediate stress-dose hydrocortisone plus fluid/resuscitation; fludrocortisone comes later as hydrocortisone is reduced.

Avoid: Fludrocortisone alone as emergency glucocorticoid coverage.

Why: Acute adrenal crisis requires glucocorticoid stress replacement and resuscitation; high-dose hydrocortisone already provides substantial mineralocorticoid activity.

Severe TBI with cerebral edema

Preferred reasoning: Use TBI/ICP-directed care rather than corticosteroids.

Avoid: Dexamethasone for traumatic brain swelling.

Why: Randomized evidence showed harm from corticosteroids in acute TBI.

Shock + cytopenias + ferritin surge + low fibrinogen

Preferred reasoning: Treat infection if plausible, urgently phenotype for HLH/MAS and involve hematology; consider trigger-directed immunomodulation including anakinra when appropriate.

Avoid: Starting anakinra solely because ferritin is high.

Why: Adult HLH/MAS therapy is individualized to syndrome, trigger, organ failure and competing infection.

High-yield protocols

Mechanism-based sequences worth memorizing

Steroid selection sequence

Define the syndrome and evidence-supported indication.
Choose molecule and regimen from that disease protocol—not from relative potency alone.
Set an explicit stop/taper/reassessment plan based on duration, disease response and prior exposure.

⚠️ A steroid regimen validated for one syndrome should not be copied unchanged into another.

Hyperinflammation checkpoint

Confirm the syndrome pattern and search for infection/malignancy/rheumatic triggers.
Trend ferritin, cytopenias, fibrinogen, triglycerides and organ failure.
Choose immune therapy with specialist input and reassess daily.

⚠️ Ferritin is a clue, not a stand-alone drug trigger.

Organ failure & special settings

When standard pharmacology stops being standard

Mechanical ventilation + NMBA

Priority: Minimize unnecessary corticosteroid/NMBA co-exposure and mobilize when feasible.

Pitfall: Ignoring cumulative ICU-acquired weakness risk.

Diabetes/HHS risk

Priority: Anticipate insulin needs and monitor glucose closely.

Pitfall: Treating steroid hyperglycemia as a reason to omit an otherwise indicated life-saving steroid.

Primary adrenal insufficiency

Priority: Separate glucocorticoid stress coverage from chronic mineralocorticoid replacement.

Pitfall: Using dexamethasone or fludrocortisone without understanding the missing hormonal component.

Possible infection + hyperinflammation

Priority: Continue infection evaluation/source control while immunomodulation is considered.

Pitfall: Assuming anti-inflammatory therapy proves the syndrome was noninfectious.

Resident progression

R1 → R5 bedside cases

Recognition becomes selection, then organ-failure adjustment, competing physiology and senior-level prioritization.

Adrenal crisis

Known primary adrenal insufficiency, vomiting, BP 72/40, Na 124, K 5.9.

Show reasoning

Give immediate stress-dose hydrocortisone and resuscitation. Do not wait for confirmatory testing; mineralocorticoid replacement becomes relevant as acute hydrocortisone is reduced.

Septic shock steroid

Norepinephrine is escalating despite appropriate source control and initial resuscitation.

Show reasoning

Hydrocortisone is reasonable according to current septic-shock guidance; avoid high-dose short-course pulses and monitor glucose/electrolytes.

ARDS choice

Early moderate-severe ARDS, no contraindication, team asks whether steroids are evidence-supported.

Show reasoning

Current SCCM guidance conditionally supports corticosteroids in adult ARDS, but does not establish one universally preferred molecule/dose/duration. Use a validated local/disease protocol.

TBI trap

Young patient with severe TBI and rising ICP; dexamethasone is suggested because CT shows edema.

Show reasoning

Do not use corticosteroids to treat acute TBI. Use evidence-based ICP/CPP management and evaluate surgically reversible lesions.

HLH versus sepsis

Persistent shock, ferritin 35,000, platelets 32, fibrinogen falling, hepatitis and EBV viremia despite broad infection workup.

Show reasoning

Manage possible infection while urgently treating a high-probability HLH phenotype with hematology-directed, trigger-specific therapy. Anakinra may fit selected phenotypes; no single drug or ferritin threshold is universal.

Full medication monograph

Hydrocortisone

Short-acting glucocorticoid with mineralocorticoid activity used in acute adrenal crisis and commonly used when corticosteroids are chosen for adult septic shock; current guidelines support corticosteroids in septic shock but do …

Dosing • renal/CRRT • toxicity • interactions →

Full medication monograph

Methylprednisolone

Potent parenteral glucocorticoid with ~5× the anti-inflammatory potency of hydrocortisone and minimal mineralocorticoid action — cornerstone therapy for severe asthma and COPD exacerbations, and non-resolving fibroproliferative A…

Dosing • renal/CRRT • toxicity • interactions →

Full medication monograph

Dexamethasone

Potent long-acting glucocorticoid with negligible mineralocorticoid activity. It is used for selected indications including adjunctive acute bacterial meningitis when given before/with initial antibiotics, symptomatic vasogenic t…

Dosing • renal/CRRT • toxicity • interactions →

Full medication monograph

Fludrocortisone

Oral mineralocorticoid used for chronic mineralocorticoid replacement in primary adrenal insufficiency and paired with hydrocortisone in the APROCCHSS septic-shock regimen; it is not a substitute for immediate stress-dose hydroco…

Dosing • renal/CRRT • toxicity • interactions →

Full medication monograph

Anakinra

IL-1 receptor antagonist used off-label in selected severe hyperinflammatory syndromes such as macrophage activation syndrome/secondary HLH. ICU dosing is syndrome- and organ-function-specific and should be specialist directed ra…

Dosing • renal/CRRT • toxicity • interactions →

Evidence & bedside-use boundary

This Masterclass teaches selection and reasoning. Exact dosing, concentration, infusion preparation, renal/hepatic/RRT adjustment and monitoring must be checked in the linked medication monograph and the institution's current formulary/protocol. Local resistance patterns and regulatory drug availability can change faster than a static teaching page.

SCCM Corticosteroid Focused Update 2024

Current recommendations for septic shock, ARDS and severe CAP.

Adult HLH Recommendations

Trigger- and severity-directed treatment principles for adult HLH.